New Data Affecting European Clinicians From Fall 2019 HIV Conferences

IDWeek 2019; October 2-6, 2019; Washington, DC
21st International Workshop on Co-morbidities and Adverse Drug Reactions in HIV; November 5-6, 2019; Basel, Switzerland
17th European AIDS Conference; November 6-9, 2019; Basel, Switzerland
Download slides with expert perspective on how data from Fall 2019 HIV conferences affect the prevention and treatment of HIV in Europe.
Chloe Orkin Photo
Chloe Orkin, MBChB, FRCP, MD
Jürgen K. Rockstroh, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 596 KB
Released: January 13, 2020

Acknowledgements

Provided by USF Health

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Gilead Sciences
ViiV Healthcare

Related Content

Slides from Dr John Baxter and Clinical Care Options (CCO): Proviral genotyping may help to inform ART choice in experienced patients who are suppressed

John D. Baxter, MD Released: January 24, 2022

Slides from Dr John Baxter and Clinical Care Options (CCO): Transmitted drug resistance does not necessarily preclude the use of many first line ART options.

John D. Baxter, MD Released: January 24, 2022

Dr Mark Sulkowski and Clinical Care Options (CCO): Treatment of both HIV and HCV should be prioritized for patients that are coinfected with careful consideration of drug-drug interactions.

Mark S. Sulkowski, MD Released: January 19, 2022

Slides from CCO: Discussion of key data and recommendations for choosing ART regimens for older patients with renal impairment or liver disease.

Jonathan Appelbaum, MD, FACP, AAHIVS Jens D. Lundgren, MD, DMSc Released: January 13, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings